filmov
tv
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a ...
Показать описание
Dr Jared Weiss speaks to ecancer about the KRYSTAL-1 trial. He discusses adagrasib as monotherapy or combined with cetuximab in patients with colorectal cancer harbouring a KRASG12C mutation. Initially, he talks about the rationale of the study.
Dr Weiss then discusses the methodology and results. The study proves that adagrasib is well tolerated as monotherapy and combined with cetuximab. It demonstrates promising clinical activity in heavily pretreated patients with KRASG12Cmutant CRC.
He concludes by mentioning that adagrasib and cetuximab are currently being evaluated in the 2L setting in a Phase 3 trial of patients with KRASG12C-mutant CRC.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
Dr Weiss then discusses the methodology and results. The study proves that adagrasib is well tolerated as monotherapy and combined with cetuximab. It demonstrates promising clinical activity in heavily pretreated patients with KRASG12Cmutant CRC.
He concludes by mentioning that adagrasib and cetuximab are currently being evaluated in the 2L setting in a Phase 3 trial of patients with KRASG12C-mutant CRC.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
0:03:48
0:02:51
0:01:22
0:03:17
0:01:00
0:01:26
0:02:26
0:05:39
0:47:22
0:01:10
0:02:30
0:07:19
0:04:29
0:05:14
0:04:46
0:06:33
0:09:21
0:34:10
0:03:30
0:29:17
0:03:44
0:02:18
0:11:17
0:00:53